![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Manfred A. Lutz, Pedro Lovato & Genaro Cuesta. (2012) Cost Analysis of Varenicline Versus Bupropion, Nicotine Replacement Therapy, and Unaided Cessation in Nicaragua. Hospital Practice 40:1, pages 35-43.
Read now
Read now
Manfred A. Lutz, Pedro Lovato & Genaro Cuesta. (2012) Cost-Effectiveness Analysis of Varenicline Versus Existing Smoking Cessation Strategies in Central America and the Caribbean Using the BENESCO Model. Hospital Practice 40:1, pages 24-34.
Read now
Read now
N Robson. (2011) Varenicline: a new pharmacotherapy for smoking cessation in primary care practice. South African Family Practice 53:3, pages 217-222.
Read now
Read now
Jon O Ebbert, Kirk D Wyatt, J Taylor Hays, Eric W Klee & Richard D Hurt. (2010) Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Preference and Adherence 4, pages 355-362.
Read now
Read now
Kari Linden, Vesa Jormanainen, Miika Linna, Harri Sintonen, Koo Wilson & Teija Kotomäki. (2010) Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Current Medical Research and Opinion 26:3, pages 549-560.
Read now
Read now
Michele A Faulkner. (2009) Smoking cessation: an economic analysis and review of varenicline. ClinicoEconomics and Outcomes Research 1, pages 25-34.
Read now
Read now
Hans Keiding. (2009) Cost–effectiveness of varenicline for smoking cessation. Expert Review of Pharmacoeconomics & Outcomes Research 9:3, pages 215-221.
Read now
Read now
Articles from other publishers (48)
Clark C. Matheos, Danny Liew, Ella Zomer & Zanfina Ademi. (2023) Cost-Effectiveness Analysis of Tobacco Control Strategies in Indonesia. Value in Health Regional Issues 33, pages 65-75.
Crossref
Crossref
Brian Chen, Gerard A. Silvestri, Jennifer Dahne, Kyueun Lee & Matthew J. Carpenter. (2022) The Cost-Effectiveness of Nicotine Replacement Therapy Sampling in Primary Care: a Markov Cohort Simulation Model. Journal of General Internal Medicine 37:14, pages 3684-3691.
Crossref
Crossref
Ricardo Ribeiro Alves Fernandes, Brayan Viegas Seixas, André Salem Szklo, Renata Leborato Guerra, Laura Augusta Barufaldi, Rita de Cássia Ribeiro de Albuquerque & Cid Manso de Mello Vianna. (2022) Cost-Effectiveness Analysis of Varenicline Versus Currently Funded Smoking Cessation Strategies in Brazil. Value in Health Regional Issues 27, pages 25-31.
Crossref
Crossref
Kyla H Thomas, Michael N Dalili, José A López-López, Edna Keeney, David Phillippo, Marcus R Munafò, Matt Stevenson, Deborah M Caldwell & Nicky J Welton. (2021) Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. Health Technology Assessment 25:59, pages 1-224.
Crossref
Crossref
Edna Keeney, Nicky J. Welton, Matt Stevenson, Michael N. Dalili, José A. López-López, Deborah M. Caldwell, David M. Phillippo, Marcus R. Munafò & Kyla H. Thomas. (2021) Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events. Value in Health 24:6, pages 780-788.
Crossref
Crossref
Jinshuo Li, Peter Hajek, Francesca Pesola, Qi Wu, Anna Phillips‐Waller, Dunja Przulj, Katie Myers Smith, Natalie Bisal, Peter Sasieni, Lynne Dawkins, Louise Ross, Maciej Lukasz Goniewicz, Hayden McRobbie & Steve Parrott. (2019) Cost‐effectiveness of e‐cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial. Addiction 115:3, pages 507-517.
Crossref
Crossref
Do-Un Jung & Sung-Jin Kim. 2019. Neuroscience of Nicotine. Neuroscience of Nicotine
467
474
.
Jonah Popp, John A. Nyman, Xianghua Luo, Jill Bengtson, Katherine Lust, Lawrence An, Jasjit S. Ahluwalia & Janet L. Thomas. (2018) Cost-effectiveness of enhancing a Quit-and-Win smoking cessation program for college students. The European Journal of Health Economics 19:9, pages 1319-1333.
Crossref
Crossref
Marrit L. Berg, Kei Long Cheung, Mickaël Hiligsmann, Silvia Evers, Reina J. A. Kinderen, Puttarin Kulchaitanaroaj & Subhash Pokhrel. (2017) Model‐based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review. Addiction 112:6, pages 946-967.
Crossref
Crossref
Adam D. M. Briggs, Jane Wolstenholme, Tony Blakely & Peter Scarborough. (2016) Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions. Population Health Metrics 14:1.
Crossref
Crossref
Emma Beard, Lion Shahab, Damian M. Cummings, Susan Michie & Robert West. (2016) New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?. CNS Drugs 30:10, pages 951-983.
Crossref
Crossref
Jiraboon Tosanguan & Nathorn Chaiyakunapruk. (2016) Cost-effectiveness analysis of clinical smoking cessation interventions in Thailand. Addiction 111:2, pages 340-350.
Crossref
Crossref
Kathleen A. Boyd, Andrew H. Briggs, Linda Bauld, Lesley Sinclair & David Tappin. (2016) Are financial incentives cost-effective to support smoking cessation during pregnancy?. Addiction 111:2, pages 360-370.
Crossref
Crossref
Lieven Annemans, Sophie Marbaix, Kristiaan Nackaerts & Pierre Bartsch. (2015) Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation. Preventive Medicine Reports 2, pages 189-195.
Crossref
Crossref
고수경, 박다진 & Juyeon Lee. (2014) 금연 치료의 재정영향 분석. The Journal of Health Technology Assessment 2:2, pages 130-136.
Crossref
Crossref
Maher Karam-Hage, Paul M. Cinciripini & Ellen R. Gritz. (2014) Tobacco use and cessation for cancer survivors: An overview for clinicians. CA: A Cancer Journal for Clinicians 64:4, pages 272-290.
Crossref
Crossref
Vance Rabius, Maher Karam-Hage, Janice A. Blalock & Paul M. Cinciripini. (2014) “Meaningful use” provides a meaningful opportunity. Cancer 120:4, pages 464-468.
Crossref
Crossref
Marjolein E. A. Verbiest, Niels H. Chavannes, Mathilde R. Crone, Mark M. J. Nielen, Dewi Segaar, Joke C. Korevaar & Willem J. J. Assendelft. (2013) An increase in primary care prescriptions of stop-smoking medication as a result of health insurance coverage in the Netherlands: population based study. Addiction 108:12, pages 2183-2192.
Crossref
Crossref
Eline Suzanne Smit, Silvia MAA Evers, Hein de Vries & Ciska Hoving. (2013) Cost-Effectiveness and Cost-Utility of Internet-Based Computer Tailoring for Smoking Cessation. Journal of Medical Internet Research 15:3, pages e57.
Crossref
Crossref
Markos Minas, Eleni Apostolidou, Irene Goudouva, Elias Makris, Konstantinos I. Gourgoulianis & Crissi Hatzoglou. (2013) Clinical phenotypes related to smoking cessation. Journal of Substance Abuse Treatment 44:3, pages 288-294.
Crossref
Crossref
Amir I.A. Ahmed, Abdullah N.A. Ali, Cees Kramers, Linda V.D. Härmark, David M. Burger & Willem M.A. Verhoeven. (2013) Neuropsychiatric Adverse Events of Varenicline. Journal of Clinical Psychopharmacology 33:1, pages 55-62.
Crossref
Crossref
Kostas Athanasakis, Michael Igoumenidis, Eleftheria Karampli, Elli Vitsou, Georgia Sykara & John Kyriopoulos. (2012) Cost-Effectiveness of Varenicline Versus Bupropion, Nicotine-Replacement Therapy, and Unaided Cessation in Greece. Clinical Therapeutics 34:8, pages 1803-1814.
Crossref
Crossref
Kristian Bolin. (2012) Economic Evaluation of Smoking-Cessation Therapies. PharmacoEconomics 30:7, pages 551-564.
Crossref
Crossref
Jennifer Prah RugerChristina M. Lazar. (2012) Economic Evaluation of Pharmaco- and Behavioral Therapies for Smoking Cessation: A Critical and Systematic Review of Empirical Research. Annual Review of Public Health 33:1, pages 279-305.
Crossref
Crossref
M. Mahmoudi, C. I. Coleman & D. M. Sobieraj. (2012) Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation. International Journal of Clinical Practice 66:2, pages 171-182.
Crossref
Crossref
Pepijn Vemer & Maureen P. M. H. Rutten-van Mölken. (2010) Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. The European Journal of Health Economics 12:5, pages 397-404.
Crossref
Crossref
Antoni Sicras Mainar, Ruth Navarro Artieda, Silvia Díaz Cerezo, Belén Martí Sánchez & Verónica Sanz De Burgoa. (2011) Tasas de abstinencia de vareniclina frente a bupropión y terapia sustitutiva con nicotina en la cesación del tabaco en atención primaria. Atención Primaria 43:9, pages 482-489.
Crossref
Crossref
James G. Xenakis, Elizabeth T. Kinter, K. Jack Ishak, Alexandra J. Ward, Jenő P. Marton, Richard J. Willke, Simon Davies & J. Jaime Caro. (2011) A Discrete-Event Simulation of Smoking-Cessation Strategies Based on Varenicline Pivotal Trial Data. PharmacoEconomics 29:6, pages 497-510.
Crossref
Crossref
Tobias Raupach & Constant P. (Onno) van Schayck. (2011) Pharmacotherapy for Smoking Cessation. CNS Drugs 25:5, pages 371-382.
Crossref
Crossref
Evelina A. Zimovetz, Koo Wilson, Miny Samuel & Stephen M. Beard. (2011) A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities. Journal of Evaluation in Clinical Practice 17:2, pages 288-297.
Crossref
Crossref
Gillian M. Keating & Katherine A. Lyseng-Williamson. (2010) Pharmacoeconomic Spotlight on Varenicline as an Aid to Smoking Cessation†. CNS Drugs 24:9, pages 797-800.
Crossref
Crossref
Jed E. Rose, Frédérique M. Behm, Tomas Drgon, Catherine Johnson & George R. Uhl. (2010) Personalized Smoking Cessation: Interactions between Nicotine Dose, Dependence and Quit-Success Genotype Score. Molecular Medicine 16:7-8, pages 247-253.
Crossref
Crossref
Pepijn Vemer, Maureen P. M. H. Rutten‐van Mölken, Janneke Kaper, Rudolf T. Hoogenveen, C. P. Van Schayck & Talitha L. Feenstra. (2010) If you try to stop smoking, should we pay for it? The cost–utility of reimbursing smoking cessation support in the Netherlands. Addiction 105:6, pages 1088-1097.
Crossref
Crossref
Gillian M. Keating & Katherine A. Lyseng-Williamson. (2010) Varenicline. PharmacoEconomics 28:3, pages 231-254.
Crossref
Crossref
Pepijn Vemer & Maureen P.M.H. Rutten-van Mölken. (2010) Crossing Borders: Factors Affecting Differences in Cost-Effectiveness of Smoking Cessation Interventions between European Countries. Value in Health 13:2, pages 230-241.
Crossref
Crossref
Dianne de Korte, Onno C. P. van Schayck, Paul van Spiegel, Ad A. Kaptein, Alfred Sachs, Maureen Rutten-van Mölken, Niels Chavannes, Trudi Tromp-Beelen, Rik Bes, Remi Allard, Gerard Peeters, Leo Kliphuis, Jan Willem Schouten, Lies van Gennip, René van Ommen & Javier Asin. (2010) Supporting smoking cessation in healthcare: obstacles in scientific understanding and tobacco addiction management. Health 02:11, pages 1272-1279.
Crossref
Crossref
Freda Patterson, Robert A. Schnoll & Caryn Lerman. 2011. Addiction Medicine. Addiction Medicine
991
1016
.
M. P. M. H. Rutten-van Mölken & T. Feenstra. 2010. Handbook of Disease Burdens and Quality of Life Measures. Handbook of Disease Burdens and Quality of Life Measures
1661
1679
.
Kristian Bolin, Koo Wilson, Hicham Benhaddi, Enrico de Nigris, Sophie Marbaix, Ann-Christin Mork & Henri-Jean Aubin. (2009) Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation—results from four European countries. European Journal of Public Health 19:6, pages 650-654.
Crossref
Crossref
Jung Youn Bae, Cheol Hwan Kim & Eui Kyung Lee. (2009) Evaluation of Cost-Utility of Varenicline Compared with Existing Smoking Cessation Therapies in South Korea. Value in Health 12, pages S70-S73.
Crossref
Crossref
Kristian Bolin, Ann-Christin Mörk & Koo Wilson. (2009) Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. Journal of Evaluation in Clinical Practice 15:3, pages 478-485.
Crossref
Crossref
David H. Au, Christopher L. Bryson, Jason W. Chien, Haili Sun, Edmunds M. Udris, Laura E. Evans & Katharine A. Bradley. (2009) The Effects of Smoking Cessation on the Risk of Chronic Obstructive Pulmonary Disease Exacerbations. Journal of General Internal Medicine 24:4, pages 457-463.
Crossref
Crossref
Gina Daubney Garrison & Sara E. Dugan. (2009) Varenicline: A first-line treatment option for smoking cessation. Clinical Therapeutics 31:3, pages 463-491.
Crossref
Crossref
Michael A. Chandler & Stephen I. Rennard. 2009. Asthma and COPD. Asthma and COPD
599
607
.
Joaquín F. Mould-Quevedo & Iris Contreras-Hernández. (2013) Análisis coste-efectividad de vareniclina (Champix®) frente a los parches de nicotina en el tratamiento del tabaquismo en México. PharmacoEconomics Spanish Research Articles 6:1, pages 22-32.
Crossref
Crossref
Kristian Bolin, Ann-Christin Mörk, Stefan Willers & Björn Lindgren. (2008) Varenicline as compared to bupropion in smoking-cessation therapy—Cost–utility results for Sweden 2003. Respiratory Medicine 102:5, pages 699-710.
Crossref
Crossref
. (2013) Varenicline stubs out the competition in smoking cessation. PharmacoEconomics & Outcomes News 539:1, pages 8-8.
Crossref
Crossref
Bart Klijs, Wilma Nusselder & Johan Mackenbach. (2009) Compression of Morbidity: A Promising Approach to Alleviate the Societal Consequences of Population Aging. SSRN Electronic Journal.
Crossref
Crossref